Press Releases
-
May 8, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care...
-
May 6, 2019First Enzyme Substitution Therapy Approved in Europe to Treat the Underlying Cause of PKU in Patients Aged 16 Years or Older at Doses up to 60 mg
BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Commission (EC) has granted marketing authorization for Palynziq® (pegvaliase injection) at doses of up to 60 mg once...
-
Apr 25, 2019- Total Revenues Top $400 million in the Quarter
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2019 2018 % Change Total Revenues $ 400.7 $ 373.4 7% Net Product Revenues Marketed...
Apr 17, 2019Company Ranks 1st Among Midsize Employers in 'Drugs & Biotechnology' IndustryBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked fourth on Forbes magazine's 2019 list of "America's Best Midsize Employers," increasing from 51st on last year's...
-
Apr 2, 2019
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday,...
